Abstract
Using a multinational registry, Nauffal et al (Eur Heart J 2021;42:3932, PMID 34491319) sought to determine whether there are differences between centers in the United States (US) and those outside the US (non-US) in the utilization of implantable cardioverter-defibrillators (ICDs) and outcome in patients with hypertrophic cardiomyopathy (HCM). The Sarcomeric Human Cardiomyopathy Registry is an association of 8 US and 5 non-US tertiary care centers collecting and maintaining data on patients with HCM, including baseline clinical data, changes in clinical data over time, and data on longitudinal follow-up and outcome.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
